Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:38:48.086Z.
Calculation as of: 2026-10-06T22:38:48.086Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d4773eeabafa62aebeff6315a1128d32b86b9098e0544dfe9acdb21c4fcfe70f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$153.58M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.64M
EV/FCF Ratio
N/A
TTM Avg
13.24x
3Y Avg
34.58x
5Y Avg
28.14x
Market Cap
$159.14M
EV/FCF Ratio
N/A
TTM Avg
568.17x
3Y Avg
568.17x
5Y Avg
88.75x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $153.79M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | N/A | 55.26x | 38.45x | 50.33x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | N/A | 13.24x | 34.58x | 28.14x |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | N/A | 568.17x | 568.17x | 88.75x |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | N/A | 175.94x | 1237.69x | 1237.69x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
